Leede Jones Gab Analyst Recommendations & Stock Picks → Elon Musk’s Controversial New Project: “Apollo” (From InvestorPlace) (Ad) This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Leede Jones Gab. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Leede Jones Gab. Country All Countries United States(NYSE & NASDAQ) United States(All Exchanges) Canada United Kingdom Sector All Sectors Aerospace Auto/Tires/Trucks Basic Materials Business Services Computer and Technology Construction Consumer Discretionary Consumer Goods Consumer Staples Finance Industrial Products Medical Miscellaneous Multi-Sector Conglomerates Oils/Energy Retail/Wholesale Services Transportation Utilities All Market Caps Large Cap ($10B+) Medium Cap ($2B-$10B) Small Cap (<$2B) Market Cap MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.Available with a MarketBeat All Access SubscriptionMarketRank™Upgrade to All Access to use the All Ranks Filter Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.Available with a MarketBeat All Access SubscriptionMedia SentimentUpgrade to All Access to use the All Sentiments Filter Analyst consensus is the average investment recommendation among Wall Street research analysts.Available with a MarketBeat All Access SubscriptionAnalyst ConsensusUpgrade to All Access to use the All Ratings Filter Export to Excel CompanyCurrent PriceRating DateActionBrokerageAnalystRatingPrice TargetImpact on PriceDetailsActionsBRCBlackrock SilverC$0.32-3.0%2/13/2024Reiterated byLeede Jones GabAnalyst R. StewartSpeculative BuyN/AView details for Leede Jones Gab rating of Blackrock Silver (CVE:BRC) on 2/13/2024PHAPremier Health of AmericaC$0.49-3.9%1/31/2024Reiterated byLeede Jones GabAnalyst D. LoeBuyN/AView details for Leede Jones Gab rating of Premier Health of America (CVE:PHA) on 1/31/2024EXEExtendicareC$7.35+0.3%11/13/2023Upgraded byLeede Jones GabAnalyst D. LoeHold -> BuyN/AView details for Leede Jones Gab rating of Extendicare (TSE:EXE) on 11/13/2023CRDLCardiol Therapeutics$1.84+4.5%9/19/2023Reiterated byLeede Jones GabAnalyst D. LoeSpeculative BuyLowView details for Leede Jones Gab rating of Cardiol Therapeutics (NASDAQ:CRDL) on 9/19/2023ACDAccord FinancialC$4.65-0.2%8/16/2023Reiterated byLeede Jones GabAnalyst G. McleishBuyN/AView details for Leede Jones Gab rating of Accord Financial (TSE:ACD) on 8/16/2023PMNProMIS Neurosciences$2.05-0.5%7/17/2023Reiterated byLeede Jones GabAnalyst D. LoeSpeculative BuyLowView details for Leede Jones Gab rating of ProMIS Neurosciences (NASDAQ:PMN) on 7/17/2023 Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. SGDSnowline GoldC$5.21-1.5%4/20/2023Reiterated byLeede Jones GabAnalyst G. McleishBuyN/AView details for Leede Jones Gab rating of Snowline Gold (CVE:SGD) on 4/20/2023CPHCipher PharmaceuticalsC$8.81+5.0%3/17/2023Reiterated byLeede Jones GabAnalyst D. LoeBuyN/AView details for Leede Jones Gab rating of Cipher Pharmaceuticals (TSE:CPH) on 3/17/2023THTXTheratechnologies$1.341/5/2023Upgraded byLeede Jones GabAnalyst D. LoeHold -> Speculative BuyLowView details for Leede Jones Gab rating of Theratechnologies (NASDAQ:THTX) on 1/5/2023THTheratechnologiesC$1.89+2.2%1/5/2023Upgraded byLeede Jones GabAnalyst D. LoeHold -> Speculative BuyN/AView details for Leede Jones Gab rating of Theratechnologies (TSE:TH) on 1/5/2023DRMedical FacilitiesC$11.14+1.2%11/11/2022Downgraded byLeede Jones GabAnalyst D. LoeBuy -> HoldN/AView details for Leede Jones Gab rating of Medical Facilities (TSE:DR) on 11/11/2022ONCOncolytics BiotechC$1.43-2.1%3/4/2022Reiterated byLeede Jones GabAnalyst D. LoeSpeculative BuyN/AView details for Leede Jones Gab rating of Oncolytics Biotech (TSE:ONC) on 3/4/2022ONCYOncolytics Biotech$1.06+1.9%3/4/2022Reiterated byLeede Jones GabAnalyst D. LoeSpeculative BuyLowView details for Leede Jones Gab rating of Oncolytics Biotech (NASDAQ:ONCY) on 3/4/2022ATBPFAntibe Therapeutics$0.2210/15/2021Downgraded byLeede Jones GabAnalyst D. LoeSpeculative Buy -> HoldHighView details for Leede Jones Gab rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 10/15/2021ATEAntibe TherapeuticsC$0.3010/15/2021Downgraded byLeede Jones GabAnalyst D. LoeSpeculative Buy -> HoldN/AView details for Leede Jones Gab rating of Antibe Therapeutics (TSE:ATE) on 10/15/2021SGDSnowline GoldC$5.21-1.5%10/7/2021Reiterated byLeede Jones GabAnalyst G. McleishBuyN/AView details for Leede Jones Gab rating of Snowline Gold (CVE:SGD) on 10/7/2021CRDLCardiol Therapeutics$1.84+4.5%8/24/2021Reiterated byLeede Jones GabAnalyst D. LoeSpeculative BuyHighView details for Leede Jones Gab rating of Cardiol Therapeutics (NASDAQ:CRDL) on 8/24/2021QIPTQuipt Home Medical$3.85+2.7%6/2/2021Reiterated byLeede Jones GabAnalyst D. LoeBuyLowView details for Leede Jones Gab rating of Quipt Home Medical (NASDAQ:QIPT) on 6/2/2021KBLK-Bro LinenC$34.75-2.0%3/19/2021Reiterated byLeede Jones GabAnalyst D. LoeBuyN/AView details for Leede Jones Gab rating of K-Bro Linen (TSE:KBL) on 3/19/2021CPHCipher PharmaceuticalsC$8.81+5.0%3/22/2021Upgraded byLeede Jones GabAnalyst D. LoeSpeculative Buy -> BuyN/AView details for Leede Jones Gab rating of Cipher Pharmaceuticals (TSE:CPH) on 3/22/2021DRMedical FacilitiesC$11.14+1.2%3/12/2021Reiterated byLeede Jones GabAnalyst D. LoeBuyN/AView details for Leede Jones Gab rating of Medical Facilities (TSE:DR) on 3/12/2021PRNProfound MedicalC$10.58+0.1%3/4/2021Reiterated byLeede Jones GabAnalyst D. LoeBuyN/AView details for Leede Jones Gab rating of Profound Medical (TSE:PRN) on 3/4/2021PROFProfound Medical$7.70-0.8%3/4/2021Reiterated byLeede Jones GabAnalyst D. LoeBuyMediumView details for Leede Jones Gab rating of Profound Medical (NASDAQ:PROF) on 3/4/2021EXEExtendicareC$7.35+0.3%3/1/2021Reiterated byLeede Jones GabAnalyst D. LoeBuyN/AView details for Leede Jones Gab rating of Extendicare (TSE:EXE) on 3/1/2021THTXTheratechnologies$1.342/26/2021Downgraded byLeede Jones GabAnalyst D. LoeSpeculative Buy -> HoldLowView details for Leede Jones Gab rating of Theratechnologies (NASDAQ:THTX) on 2/26/2021THTheratechnologiesC$1.89+2.2%2/26/2021Downgraded byLeede Jones GabAnalyst D. LoeSpeculative Buy -> HoldN/AView details for Leede Jones Gab rating of Theratechnologies (TSE:TH) on 2/26/2021ONCOncolytics BiotechC$1.43-2.1%2/24/2021Reiterated byLeede Jones GabAnalyst D. LoeSpeculative BuyN/AView details for Leede Jones Gab rating of Oncolytics Biotech (TSE:ONC) on 2/24/2021ONCYOncolytics Biotech$1.06+1.9%2/24/2021Reiterated byLeede Jones GabAnalyst D. LoeSpeculative BuyHighView details for Leede Jones Gab rating of Oncolytics Biotech (NASDAQ:ONCY) on 2/24/2021 MarketBeat Community Rating for Leede Jones GabCommunity Ranking: 2.4 out of 5 (2.4 of 5 stars)Outperform Votes: 6,356 (Vote Outperform)Underperform Votes: 6,711 (Vote Underperform)Total Votes: 13,067MarketBeat's community ratings are surveys of what our community members think about Leede Jones Gab and other research firms. Vote "Outperform" if you believe Leede Jones Gab's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Leede Jones Gab's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days. Stock Ratings Reports and Tools Today's Ratings: U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks: Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools: Stock Ratings by Company Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Ratings for Popular Stocks: Alphabet (Google) Amazon Apple Meta (Facebook) Microsoft Netflix Nvidia Tesla Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
